<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>In this review we discuss the adrenergic pathways for alpha 1 and alpha 2 receptors and the current as well as potential future medication targeting these receptors. Overall, there is ongoing research into a multitude of directions with a promising outlook for alpha 1 and alpha 2 adrenergic receptors. The alpha 1-adrenergic receptor subfamily is currently modulating only a modest number of nervous system functions due the fact, that only a relatively small number of selective commercial products are available. Chronic stress can affect the long-term depression of alpha 1 receptors. Recent studies are searching for new molecular targets which might act on these receptors. Presynaptic alpha 2 receptors play an important role in modulating release of several neurotransmitters in the central nervous system. The future of alpha 2 adrenergic receptors in clinical practice looks even more promising and versatile than that of alpha 1 adrenergic receptors. Alpha 2 adrenergic receptors show different responses, especially regarding hypertension and heart failure treatment, and current research suggests a genetic component as a cause, which is being explored further.</p>
</abstract>

In this review we discuss the adrenergic pathways for alpha 1 and alpha 2 receptors and the current as well as potential future medication targeting these receptors. Overall, there is ongoing research into a multitude of directions with a promising outlook for alpha 1 and alpha 2 adrenergic receptors. The alpha 1-adrenergic receptor subfamily is currently modulating only a modest number of nervous system functions due the fact, that only a relatively small number of selective commercial products are available. Chronic stress can affect the long-term depression of alpha 1 receptors. Recent studies are searching for new molecular targets which might act on these receptors. Presynaptic alpha 2 receptors play an important role in modulating release of several neurotransmitters in the central nervous system. The future of alpha 2 adrenergic receptors in clinical practice looks even more promising and versatile than that of alpha 1 adrenergic receptors. Alpha 2 adrenergic receptors show different responses, especially regarding hypertension and heart failure treatment, and current research suggests a genetic component as a cause, which is being explored further.

Alpha adrenergic receptors in clinical practice – Present and future

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures

Acta Marisiensis - Seria Medica

This work is licensed under the Creative Commons Attribution 4.0 International License.

{"article-title":"Alpha adrenergic receptors in clinical practice \u2013 Present and future"}

In this review we discuss the adrenergic pathways for alpha 1 and alpha 2 receptors and the current as well as potential future medication targeting these...

Alpha adrenergic receptors in clinical practice – Present and future

Publié en ligne: 07 janv. 2023

Pages: 145 - 149

Reçu: 28 nov. 2022

Accepté: 07 déc. 2022

DOI: https://doi.org/10.2478/amma-2022-0030

Mots clés
alpha adrenergic receptors, molecular target, immunity, noradrenaline, pharmacotherapy

© 2022 Patrick Lechsner et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Alpha adrenergic receptors in clinical practice – Present and future

Publié en ligne: 07 janv. 2023

Pages: 145 - 149

Reçu: 28 nov. 2022

Accepté: 07 déc. 2022

DOI: https://doi.org/10.2478/amma-2022-0030

Mots clésalpha adrenergic receptors, molecular target, immunity, noradrenaline, pharmacotherapy

© 2022 Patrick Lechsner et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Mots clés
alpha adrenergic receptors, molecular target, immunity, noradrenaline, pharmacotherapy